From USD 1.9 billion in 2022 to USD 3.8 billion by 2031, the worldwide anaphylaxis treatment market is expected to rise at a CAGR of 8.2%. Over the whole projection period, North America is predicted to control the market.
Growing awareness of anaphylaxis, changes in treatment choices, and rising global allergy incidence all help to drive the notable expansion in the market for anaphylaxis therapy. Furthermore, influencing market growth are rising healthcare costs and better access to emergency drugs. On the other hand, exorbitant expenses related to various therapies and ignorance in underdeveloped areas might somewhat impede progress.
Market Trend: Increasing acceptance of epinephrine self-injectable devices.
Self-injectable epinephrine devices are being used very noticeably in the market for anaphylactic therapy. During extreme allergic responses, these auto-injectors provide patients a rapid and simple approach to delivering life-saving medicine. Patients and medical professionals have become especially fond of these gadgets because of their mobility, simplicity, and ease. Advanced auto-injectors with features like voice instructions, needle protection mechanisms, and dosage tracking capabilities are the focus of manufacturers on development. As it enables patients to properly control anaphylaxis in emergency conditions, therefore possibly lowering hospitalizations and improving outcomes. This tendency is predicted to keep driving market growth.
Market Driver: Growing worldwide allergy and anaphylactic prevalence.
anaphylaxis treatment market is primarily driven by the growing global incidence of allergies and anaphylaxis occurrences. Rising allergy symptoms have been caused in part by changing lifestyles, environmental pollutants, and eating habits. Recent research indicate that in industrialized nations, anaphylaxis's frequency has been rising by 5–7% a year. Anaphylaxis treatments—including epinephrine auto-injectors, antihistamines, and corticosteroids—have been more sought after in response to this increase in incidence. Regulatory agencies and healthcare systems are also concentrating on enhancing anaphylaxis control strategies and expanding availability of emergency drugs. Over the projection period, the expanding patient pool and increasing awareness of the illness should drive market development.
Market Restraints: include limited availability in underdeveloped areas and high cost of epinephrine auto-injectors.
The great expense of epinephrine auto-injectors and restricted availability of these devices in underdeveloped areas constitute a major obstacle in the market for anaphylaxis therapy. Particularly in nations with limited healthcare coverage, individuals, healthcare professionals, and legislators have been concerned about the cost of branded auto-injectors. For those who run the risk of anaphylaxis, this financial element might cause patients to stray from recommended treatment programs and maybe cause disastrous circumstances. Furthermore, many underdeveloped nations lack knowledge about anaphylaxis and have few choices for sophisticated therapy. Lack of strong healthcare infrastructure and reimbursement rules in these areas aggravates the availability to life-saving drugs even further. These elements together impede market development and provide difficulties for industry participants seeking worldwide presence.
Epinephrine dominates the area of drugs classified as
first-line therapy for anaphylaxis is epinephrine, which quickly and powerfully reverses symptoms. Its vital importance in emergency management explains great demand and market share.
Because it may rapidly undo potentially fatal symptoms, epinephrine is still the gold standard therapy for anaphylaxis. It acts by relaxing airways, narrowing blood vessels, and lowering edema. Epinephrine's availability in several forms—including auto-injectors—has enhanced its accessibility and simplicity of usage. Healthcare policies all over advise quick epinephrine injection as the main intervention for anaphylaxis, therefore confirming its dominating presence in the market. To maintain its leadership in the field of anaphylaxis therapy, continuous research and development initiatives aiming at enhancing epinephrine administration systems and increasing their stability could be anticipated.
market for anaphylaxis therapy is led by North America.
North America's supremacy in the anaphylaxis treatment market is driven by high incidence of allergies, modern healthcare infrastructure, and strong presence of important industry competitors.
Due in great part to the high frequency of allergies and anaphylaxis cases in North America, the country has the biggest stake in the worldwide anaphylaxis treatment market. Over the last several years, food allergies and other allergy disorders have become especially common in the United States. The area's market leadership stems from its sophisticated healthcare system, set payment rules, and high degree of knowledge among patients and healthcare professionals. Furthermore, supporting North America's position are the existence of big pharmaceutical corporations and continuous research and development operations in anaphylaxis control. Regulatory authorities in the area have also taken aggressive steps to guarantee market expansion by means of improved access to epinephrine auto-injectors and other anaphylactic treatments.
Strong rivalry among both major pharmaceutical firms and new competitors defines the anaphylaxis treatment industry. To maintain their market positions, key market players concentrate on product innovation, strategic alliances, and geographical growth. To provide better medication delivery technologies and enhance current therapies, big corporations actively engage in research and development. To solve cost issues, the market has witnessed more attempts toward creating generic epinephrine auto-injectors. As businesses try to increase their product lines and boost their market share, mergers and acquisitions have also been somewhat common. Furthermore, there is increasing rivalry in the creation of new treatments for long-term management and anaphylaxis avoidance, which can change the competitive scene in next years.
Mylan N.V.
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Adamis Pharmaceuticals Corporation
ALK Abelló A/S
Abbott Laboratories
Amneal Pharmaceuticals LLC
Kaleo Inc.
DBV Technologies
Bausch Health Companies Inc.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022-2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Anaphylaxis Treatment Market (2018 – 2022)
3.2. Global Anaphylaxis Treatment Market (2023 –2031)
3.2.1. Market Segment By Drug Class (2023 –2031)
3.2.2. Market Segment By Route of Administration (2023 –2031)
3.2.3. Market Segment By Distribution Channel (2023 –2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Growing adoption of self-injectable epinephrine devices
4.1.2. Increasing focus on personalized anaphylaxis management
4.1.3. Rising demand for combination therapies
4.2. Market Drivers
4.2.1. Rising prevalence of allergies and anaphylaxis cases globally
4.2.2. Advancements in drug delivery technologies
4.2.3. Growing awareness and improved diagnosis rates
4.3. Market Restraints
4.3.1. High cost of epinephrine auto-injectors and limited access in developing regions
4.3.2. Stringent regulatory requirements
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY DRUG CLASS (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Epinephrine
5.2. Antihistamines
5.3. Corticosteroids
6. BY ROUTE OF ADMINISTRATION
6.1. Oral
6.2. Injectable
6.3. Others
7. BY DISTRIBUTION CHANNEL
7.1. Hospital Pharmacies
7.2. Retail Pharmacies
7.3. Online Pharmacies
8. GEOGRAPHY
8.1. North America
8.1.1. United States
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Rest of South America
8.3. Europe
8.3.1. Germany
8.3.2. United Kingdom
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle-East
8.5.1. UAE
8.5.2. Saudi Arabia
8.5.3. Turkey
8.5.4. Rest of Middle East
8.6. Africa
8.6.1. South Africa
8.6.2. Egypt
8.6.3. Rest of Africa
9. COMPETITIVE LANDSCAPE
9.1. Key Developments
9.2. Company Market Share Analysis
9.3. Product Benchmarking
10. SWOT ANALYSIS
11. COMPANY PROFILES
11.1. Mylan N.V.
11.2. Pfizer Inc.
11.3. Teva Pharmaceutical Industries Ltd.
11.4. Adamis Pharmaceuticals Corporation
11.5. ALK-Abelló A/S
11.6. Abbott Laboratories
11.7. Amneal Pharmaceuticals LLC
11.8. Kaleo, Inc.
11.9. DBV Technologies
11.10. Bausch Health Companies Inc.
12. MARKET OPPORTUNITIES
By Drug Class:
Epinephrine
Antihistamines
Corticosteroids
By Route of Administration:
Oral
Injectable
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
